Navigation Links
Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
Date:4/1/2008

r to provide fast and precise patient temperature control.

About Cardium

Cardium Therapeutics, Inc. and its subsidiaries, InnerCool Therapies, Inc. and the Tissue Repair Company, are medical technology companies primarily focused on the development, manufacture and sale of innovative therapeutic products and devices for cardiovascular, ischemic and related indications. Cardium's lead product candidate, Generx(TM) (alferminogene tadenovec, Ad5FGF4), is a DNA-based growth factor therapeutic being developed for potential use by interventional cardiologists as a one-time treatment to promote and stimulate the growth of collateral circulation in the hearts of patients with ischemic conditions such as recurrent angina. For more information about Cardium and its businesses, products and therapeutic candidates, please visit http://www.cardiumthx.com or view its 2006 Annual Report at http://www.cardiumthx.com/flash/pdf/2006CardiumAnnualReport.pdf.

Cardium's InnerCool Therapies subsidiary is a San Diego-based medical technology company in the emerging field of patient temperature modulation therapy to rapidly and controllably cool the body in order to reduce cell death and damage following acute ischemic events such as cardiac arrest or stroke, and to potentially lessen or prevent associated injuries such as adverse neurological outcomes. For more information about Cardium's InnerCool subsidiary and patient temperature modulation, including InnerCool's Celsius Control System(TM), which has received regulatory clearance in the U.S., Europe and Australia, please visit http://www.innercool.com.

Cardium's Tissue Repair Company subsidiary (TRC) is a San Diego-based biopharmaceutical company focused on the development of growth factor therapeutics for the tre
'/>"/>

SOURCE Cardium Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Teva Pharmaceuticals Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis
2. Pipeline for Lung Cancer Therapies is Focus of New MedPredict Report
3. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
4. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
5. Fate Therapeutics Created by Leading Stem Cell Scientists to Pursue New Approaches to Stem Cell Therapies
6. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
7. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
8. Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD)
9. Tengion Announces European Orphan Drug Designation for Neo-Bladder Augment
10. DiObex Announces Presentation of Scientific Poster at Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
11. DaVita Announces Retirement of Former Chief Medical Officer Charles J. McAllister, M.D.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... Clara CA (PRWEB) , ... June 30, 2015 ... ... microscopy (AFM) is hosting a webinar to provide advanced scientific research into new ... science, bio science and energy. Touted as 'the wonder material of the ...
(Date:6/30/2015)... -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP ), a specialty ... unmet medical needs in women,s health, today announced ... at the Cantor Fitzgerald Inaugural Healthcare Conference as ... PM EDTLocation: , Le Parker Meridien Hotel, New ... under  ,Investor, or  click here The ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... provide new insights on mechanics of fecal microbiota transplantation in C. difficile patients. ... the microbiome of patients undergoing fecal microbiota transplantation (FMT) as a treatment for ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... the federal government, announced in a paper published this week in the scientific ... problem with the diagnostic techniques currently used to detect the Ebola virus. Noblis ...
Breaking Biology Technology:How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 3How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 4Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 2Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 3Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 4
... Emerging Therapies Will Not Match, the Current ... According to a New ... Decision Resources, one of the,world,s leading research and ... emerging drug Zactima from AstraZeneca,will earn 4.7 percent patient ...
... ) will report financial results for the year ended December,31, ... 27, 2008. The,Company has scheduled a conference call for Thursday, ... Interested parties can access the call by dialing (877) ... web cast, which can be,found at http://www.bioheartinc.com . A ...
... SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP ) will be ... hosted by BioCentury and Thomson on Thursday, March 27,2008 ... and chief,executive officer of SGX Pharmaceuticals, will provide an ... held at the Millennium,Broadway Hotel and Conference Center in ...
Cached Biology Technology:AstraZeneca's Zactima to Earn Almost Five Percent Patient Share in the Treatment of Non-Small-Cell Lung Cancer by 2016 2Bioheart, Inc. to Report Full Year 2007 Financial Results on Thursday, March 27, 2008 2
(Date:6/10/2015)... DALLAS , June 10, 2015 ... report "3D Sensor Market by Technology (Ultrasound, TOF, ... Application (consumer Electronics, Entertainment, Automotive) and by Geography ... published by MarketsandMarkets, the market is expected to ... CAGR of 25.51% between 2015 and 2020. ...
(Date:6/9/2015)... , June 09, 2015 Research ... addition of the "Gesture Recognition & Touchless ... (Consumer Electronics, Automotive, & Others), Product (Biometric & ... to 2020" report to their offering. ... market is expected to reach $ 23.55 Billion ...
(Date:6/8/2015)... , June 8, 2015  The ... today their selection of Troy Potter ... effective immediately. SIBA is a non-profit association that ... responsible policy, education and implementation of solutions that ... platforms. ...
Breaking Biology News(10 mins):3D Sensor Market Worth $3,319.71 Million by 2020 23D Sensor Market Worth $3,319.71 Million by 2020 33D Sensor Market Worth $3,319.71 Million by 2020 4Global Gesture Recognition & Touchless Sensing (Technology, Application & Products) Market 2015-2020 2Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 2Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 3Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 4Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 5
... team of scientists from the UCLA Departments of Surgery ... three-year, $2 million grant from the W.M. Keck Foundation ... donor livers. Dr. Jerzy W. Kupiec-Weglinski, principal investigator ... Research Center, said he hopes his research will address ...
... must obey the laws of physics including the ... disorder, or entropy, can only grow. Highly ordered cells ... actually do conform because they generate heat that increases ... is the theoretical threshold for how much heat a ...
... gene for a specific protein face a 20-fold greater risk ... mBio , the online open-access journal of the American ... the most common cause of fungal meningitis among HIV-infected individuals. ... who has a very low level of CD4+ T cells, ...
Cached Biology News:UCLA scientists receive $2 million grant to improve quality of donor livers for transplant 2How quickly can a bacterium grow? 2How quickly can a bacterium grow? 3Gene makes some HIV-infected patients more at risk for fungal disease 2Gene makes some HIV-infected patients more at risk for fungal disease 3
...
...
Mouse polyclonal antibody to TNPO2 - transportin 2 (importin 3, karyopherin beta 2b)...
Mouse monoclonal antibody to CDC2L5 - cell division cycle 2-like 5 (cholinesterase-related cell division controller)...
Biology Products: